These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28378877)

  • 1. Occlusion in the Flow of New Drugs for Cardiovascular Disease.
    Ringel MS; Shah NA; Baedeker M; Lim CT; Lamichhane A; Schulze U
    Clin Pharmacol Ther; 2017 Aug; 102(2):246-253. PubMed ID: 28378877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the Development of Novel Cardiovascular Therapies.
    Hwang TJ; Kesselheim AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):194-196. PubMed ID: 28643861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular pipeline decline quantified.
    Mullard A
    Nat Rev Drug Discov; 2016 Sep; 15(10):669. PubMed ID: 27681785
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular pharmacology in the post-blockbuster era.
    Brandes RP
    Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 6. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 7. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of available ones.
    Shantsila A; Lip GY
    Int J Clin Pract; 2010 Jan; 64(2):138-40. PubMed ID: 20089004
    [No Abstract]   [Full Text] [Related]  

  • 8. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacoeconomics and cardiovascular disease].
    Anguita Sánchez M
    Rev Clin Esp; 2004 Aug; 204(8):391-2. PubMed ID: 15274760
    [No Abstract]   [Full Text] [Related]  

  • 10. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost-effectiveness of cardiovascular medicine: victims of our own success?
    Vardas PE
    Hellenic J Cardiol; 2013; 54(2):155-6. PubMed ID: 23557621
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Past the wall in cardiovascular R&D.
    Topol EJ
    Nat Rev Drug Discov; 2009 Apr; 8(4):259. PubMed ID: 19348004
    [No Abstract]   [Full Text] [Related]  

  • 15. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 16. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility].
    Schmidt K
    Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969
    [No Abstract]   [Full Text] [Related]  

  • 17. ACE inhibitors: back to prime time?
    Gupta M; Verma S; Mancini GB
    Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166
    [No Abstract]   [Full Text] [Related]  

  • 18. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
    Burock S; Meunier F; Lacombe D
    Eur J Cancer; 2013 Sep; 49(13):2777-83. PubMed ID: 23777742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.